Category: Clinical Trials

Researchers are launching a promising new Phase III clinical trial, known as the IMPACT Trial, to evaluate an innovative treatment approach for patients facing unresectable appendix or colorectal cancer that has spread to the lining of the abdominal cavity, a condition known as peritoneal metastases. This is a particularly challenging diagnosis, and the trial represents a hopeful step toward expanding treatment options for these patients.

The study will examine Pressurized Intraperitoneal Aerosolized Chemotherapy, or PIPAC, using the drug mitomycin. Unlike traditional chemotherapy infusions delivered through a vein, PIPAC works by delivering chemotherapy as a fine, pressurized mist directly into the abdominal cavity during a minimally invasive laparoscopic procedure. This technique allows the medication to be absorbed more evenly by cancerous tissue while avoiding the need for more invasive open surgery, and it can potentially be repeated multiple times as needed.

In the trial, patients will receive PIPAC with mitomycin in combination with the standard FOLFIRI chemotherapy regimen, with or without the antiangiogenic drug bevacizumab, and researchers will compare outcomes to those receiving standard FOLFIRI plus bevacizumab alone. The goal is to determine whether this combined, localized-and-systemic approach can offer better results than standard intravenous chemotherapy by itself.

What makes this approach especially encouraging is its minimally invasive nature and the potential for more targeted, effective delivery of cancer-fighting medication directly where it’s needed most. For patients whose tumors cannot be surgically removed, having additional treatment options that are both innovative and less physically taxing represents meaningful progress in the field of oncology. Trials like IMPACT reflect the ongoing efforts of the medical research community to refine and improve care for people facing difficult-to-treat cancers.

While it will take time before results are available, the initiation of this Phase III trial marks an important and hopeful development for patients and families affected by appendix and colorectal cancers with peritoneal spread. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Biotechnology company Nuritas has announced encouraging results for its PeptiSleep ingredient, a bioactive peptide identified through the company’s AI-powered discovery platform. According to reporting from Nutraceutical Business Review, the peptide has shown the ability to support improved sleep quality alongside favorable changes in heart rate variability (HRV), a key marker often associated with better recovery and overall autonomic nervous system balance.

Sleep support is one of the fastest-growing areas of interest in the wellness and nutraceutical space, with many consumers seeking natural alternatives to conventional sleep aids. Peptides like PeptiSleep represent a growing category of bioactive compounds derived from natural sources and refined using advanced computational tools to identify molecules with targeted physiological effects. Nuritas has built its reputation on using artificial intelligence to scan vast libraries of naturally occurring peptides, aiming to uncover ingredients with meaningful health benefits.

The connection between sleep quality and HRV is notable because HRV is frequently used as an indicator of how well the body manages stress and recovers during rest. Improvements in this measure, paired with subjective or objective gains in sleep quality, suggest that PeptiSleep may be influencing the body’s relaxation and recovery processes in a beneficial way. This kind of dual benefit could be appealing to companies formulating supplements aimed at stress relief, recovery, and nighttime wellness.

For the nutraceutical industry, findings like these highlight the continued momentum behind peptide-based ingredients as functional additions to sleep and wellness products. As interest in natural, science-backed solutions for sleep continues to rise, ingredients supported by real-world data may find growing traction among formulators and consumers alike. Nuritas’ work also reflects a broader trend of using AI to accelerate the discovery of novel peptides with specific, targeted benefits rather than relying solely on traditional trial-and-error methods.

While these results are promising, further peer-reviewed research and larger-scale studies will help clarify the full scope of PeptiSleep’s benefits and how it might best be used within sleep-support formulations. As always, this article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Nuritas’ PeptiSleep shows improved sleep quality and HRV – Nutraceutical Business Review

Italian biotechnology company Kither Biotech has announced the successful completion of a Phase 1 clinical trial for its peptide-based therapeutic candidate, a milestone that brings the company one step closer to offering new treatment options for patients with respiratory conditions. The trial, designed to evaluate the safety and tolerability of the investigational peptide, represents an important early validation for the company’s approach to drug development.

Kither Biotech has focused its research on developing selective inhibitors aimed at addressing inflammatory and respiratory diseases, an area where new therapeutic options are always welcome. Peptide-based drugs are increasingly recognized for their ability to precisely target specific biological pathways, potentially offering more focused treatment effects compared to some traditional small-molecule drugs. The successful completion of this Phase 1 trial suggests that the company’s candidate performed as expected in this initial testing phase, a positive sign for its continued development.

Completing Phase 1 trials is a critical step in the broader drug development pipeline, as it typically provides the first evidence of how a new compound behaves in humans, including how well it is tolerated at various doses. Achieving this milestone allows a company to move forward with greater confidence into subsequent trial phases, which are typically designed to further explore efficacy in patients who could benefit from the treatment.

This achievement adds to the growing body of evidence that peptide therapeutics continue to advance through the clinical pipeline, offering hope for new treatment approaches in areas of significant unmet medical need. As Kither Biotech moves toward the next stages of clinical development, the broader scientific and medical community will be watching closely to see how this peptide-based candidate performs in later-stage trials.

This article is for informational purposes only and does not constitute medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Kither Biotech successfully completes Phase 1 clinical – GlobeNewswire

Arch Biopartners has announced plans to expand its ongoing clinical trial of the LSALT peptide into the United States, marking a significant step forward for the company’s research program. LSALT peptide is being studied as a potential therapeutic option, and this expansion reflects growing confidence in the compound’s development pathway as well as an effort to broaden the pool of patients who can participate in the research.

Expanding a clinical trial into new geographic markets like the US often signals that a therapy has cleared important early hurdles and that sponsors see enough promise to invest in larger-scale, more diverse patient enrollment. Access to the US clinical trial infrastructure can also mean faster recruitment, access to specialized medical centers, and the possibility of engaging with regulators such as the FDA earlier in the development process.

For patients and researchers following peptide-based therapeutics, this kind of expansion is an encouraging sign. It suggests that Arch Biopartners is building a more robust body of clinical evidence, which is a critical part of moving any investigational treatment closer to potential approval. Broader trial participation can also help ensure that findings are more representative and applicable across different patient populations.

While it’s still early in the process, developments like this highlight the ongoing momentum in the peptide therapeutics space, where companies continue to invest in expanding research infrastructure to better understand how these molecules might benefit patients. As the trial progresses in the US, the peptide research community will be watching for updates on enrollment, study design, and eventual results.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Arch Biopartners plans US expansion of LSALT peptide trial – Yahoo

A new clinical trial registered on ClinicalTrials.gov is set to investigate an important question for anyone interested in weight management: can the amino acid leucine help preserve muscle mass during structured fasting periods? The study will enroll 100 young men between the ages of 21 and 35 to complete a four-week alternate-day fasting (ADF) program, with researchers testing four different leucine doses to see whether a dose-response relationship exists for muscle maintenance.

Alternate-day fasting has grown in popularity as a weight management strategy, but one common concern is that fasting periods can sometimes lead to loss of lean muscle mass alongside fat loss. This trial aims to address that concern directly by pairing a carefully controlled fasting protocol with varying leucine intake—ranging from 0.02 to 0.08 grams per kilogram of body weight per meal. Leucine is a branched-chain amino acid long recognized for its role in stimulating muscle protein synthesis, making it a logical candidate for this kind of investigation.

What makes this study particularly promising is its rigor: all meals will be provided to participants, ensuring consistent protein and caloric intake across fasting and feeding days, and the leucine dosing will be double-blind to reduce bias in the results. Researchers will track a wide range of outcomes, including body composition, blood parameters, waist-to-hip ratio, mood, stress levels, and appetite-related measures before and after the four-week program. This comprehensive approach could yield valuable insights not just into muscle preservation, but into the broader physical and psychological effects of combining targeted amino acid supplementation with intermittent fasting.

If the hypothesized dose-response relationship holds true, the findings could help shape more effective, muscle-sparing approaches to fasting-based weight loss programs. This could be especially meaningful for individuals seeking to manage body composition without sacrificing lean tissue—a common challenge in many weight loss strategies. Because the study focuses on generally healthy young men without underlying cardiovascular, metabolic, or kidney conditions, it also reflects a thoughtfully controlled research design aimed at generating clear, interpretable data.

As this trial gets underway, it represents an encouraging step toward better understanding how simple nutritional strategies, like optimizing leucine intake, might support healthier outcomes during periods of caloric restriction. Results from studies like this one could eventually inform more personalized and effective approaches to weight management that prioritize preserving muscle alongside fat loss. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Dose Response of Leucine on Muscle Maintenance During Weight Loss